Literature DB >> 7591270

Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.

E A Musgrove1, R Lilischkis, A L Cornish, C S Lee, V Setlur, R Seshadri, R L Sutherland.   

Abstract

Aberrant cyclin expression has been implicated in oncogenesis in a number of human cancers. Since altered function of regulators of cyclin-dependent kinase (CDK) activity other than cyclins, in particular CDK inhibitors, might play a similar role in oncogenesis, we examined the expression and regulation of the CDK inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer cell lines. Both the INK4 and INK4B genes were homozygously deleted in 3 cell lines, while INK4 alone was deleted in 2 cell lines. A further 2 cell lines displayed loss of an allele at this locus, and in 1 of these the remaining allele contained a mis-sense mutation within the coding region of the p16INK4 protein. The majority of cell lines examined, including 2 normal mammary epithelial cell strains, expressed low levels of INK4 mRNA and low or undetectable levels of INK4B mRNA. However, INK4 mRNA was expressed at high levels in 5 cell lines, and this was associated with deletion or inactivation of the retinoblastoma susceptibility gene product pRB but not with mutation of TP53. No deletions of the WAF1/CIP1 gene were observed, but WAF1/CIP1 mRNA levels were reduced in cell lines with TP53 mutation. Transfection of a p16INK4 expression vector into MDA-MB-231 cells lacking the INK4 gene failed to produce any p16INK4-expressing cell lines, suggesting that such cells were selected against in continuous culture. Despite the frequent deletion of INK4 in breast cancer cell lines, no evidence was obtained for INK4 deletions in DNA from 45 primary breast carcinomas. Thus, homozygous deletion of the INK4 gene appears to be a rare event in primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591270     DOI: 10.1002/ijc.2910630420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin.

Authors:  Tohru Yamada; Yoshinori Hiraoka; Masateru Ikehata; Kazuhide Kimbara; Benjamin S Avner; Tapas K Das Gupta; Ananda M Chakrabarty
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

3.  Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.

Authors:  M D Planas-Silva; R A Weinberg
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.

Authors:  S Cariou; J C Donovan; W M Flanagan; A Milic; N Bhattacharya; J M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 5.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 6.  Cell cycle regulators and their abnormalities in breast cancer.

Authors:  P L Fernández; P Jares; M J Rey; E Campo; A Cardesa
Journal:  Mol Pathol       Date:  1998-12

7.  Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression.

Authors:  S Siavoshian; J P Segain; M Kornprobst; C Bonnet; C Cherbut; J P Galmiche; H M Blottière
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

8.  Cyclin E, a redundant cyclin in breast cancer.

Authors:  J Gray-Bablin; J Zalvide; M P Fox; C J Knickerbocker; J A DeCaprio; K Keyomarsi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 9.  Cyclins and breast cancer.

Authors:  E A Musgrove; R Hui; K J Sweeney; C K Watts; R L Sutherland
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

10.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.